Products for Research Use Only

MK2-IN-1

CAT: 0804-HY-12834-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12834-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MK2-IN-1 (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC50 of 0.11 uM for MK2 and an EC50 of 0.35 uM for pHSP27. MK2-IN-1 impaires the phosphorylation level of serine residues in the Tfcp2l1 protein[1][2].
CAS Number
1314118-92-7
UNSPSC
12352005
Target
HSP; MAPKAPK2 (MK2)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/MK2-IN-1.html
Purity
99.04
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(C2=CC=C(Cl)C=C2)O1)N(C3=CC=C(N4CCNCC4)C=C3)CC5=NC=CC=C5
Molecular Formula
C27H25ClN4O2
Molecular Weight
472.97
References & Citations
[1]Rao AU, et al. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors. Bioorg Med Chem Lett. 2012 Jan 15;22 (2) :1068-72.|[2]Yan Zhang, et al. MK2 promotes Tfcp2l1 degradation via β-TrCP ubiquitin ligase to regulate mouse embryonic stem cell self-renewal. Cell Rep. 2021 Nov 2;37 (5) :109949.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Biol Pharm Bull. 2025;48 (2) :172-176.|Cell Rep. 2021 Nov 2;37 (5) :109949.|J Pharmacol Exp Ther. 2019 Aug;370 (2) :219-230.|Cell Death Dis. 2021 Oct 23;12 (11) :994.|University of Minnesota. 2025.